Company intelligence / Profile preview

NINE B

Bunkyo-ku, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Nine B is a Japanese biotechnology company focused on the discovery and development of novel antibody therapeutics and diagnostic agents. Spun out from the University of Tokyo, the company utilizes a proprietary B-cell analysis platform to identify high-affinity antibodies for challenging targets. Their research primarily targets oncology and inflammatory diseases, aiming to address unmet medical needs through precision immunology. The company is backed by prominent venture capital firms including University of Tokyo Edge Capital Partners (UTEC).

Therapeutic areas: ImmunologyOncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on NINE B.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NINE B.

Explore the full profile